Literature DB >> 2106917

Apolipoprotein AIMilano. Partial lecithin:cholesterol acyltransferase deficiency due to low levels of a functional enzyme.

G Franceschini1, M Baio, L Calabresi, C R Sirtori, M C Cheung.   

Abstract

The cholesterol esterification process was analyzed in 19 carriers of the apolipoprotein AIMilano (AIM) variant and in 19 age-sex matched controls by measuring lecithin:cholesterol acyltransferase (LCAT) mass, activity (i.e., cholesterol esterification with a standard proteoliposome substrate) and cholesterol esterification rate (i.e., cholesterol esterification in the presence of the endogenous substrate). The AIM subjects had lower LCAT mass (3.30 +/- 0.85 micrograms/ml), activity (71.1 +/- 36.4 nmol/ml per h) and cholesterol esterification rate (23.6 +/- 12.5 nmol/ml per h) compared to controls (5.22 +/- 0.74 micrograms/ml, 121.6 +/- 54.6 nmol/ml per h and 53.6 +/- 29.9 nmol/ml per h, respectively). The specific LCAT activity, i.e., LCAT activity per microgram of LCAT, was similar in the two groups, indicating that the LCAT protein in the AIM carriers is structurally and functionally normal. However, the specific cholesterol esterification rate was 23% lower in the AIM subjects (8.03 +/- 6.01 nmol/h per microgram) compared to controls (10.49 +/- 5.86 nmol/h per microgram; P less than 0.05). The capacity of HDL3, purified from both AIM and control plasma, to act as substrates for cholesterol esterification was similar, thus suggesting that other mechanism(s) may be in play. Carriers with a relative abundance of abnormal, small HDL3b particles had the most altered cholesterol esterification pattern. Upon evaluating all AIM subjects, a complex relationship between HDL structure, plasma lipid-lipoprotein levels and cholesterol esterification emerged, making the AIMilano condition a unique model for the study of the mechanisms regulating the cholesterol esterification-transfer process in man.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2106917     DOI: 10.1016/0005-2760(90)90102-4

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  5 in total

1.  Effect of repeated apoA-IMilano/POPC infusion on lipids, (apo)lipoproteins, and serum cholesterol efflux capacity in cynomolgus monkeys.

Authors:  Herman J Kempen; Monica Gomaraschi; S Eralp Bellibas; Stephanie Plassmann; Brad Zerler; Heidi L Collins; Steven J Adelman; Laura Calabresi; Peter L J Wijngaard
Journal:  J Lipid Res       Date:  2013-07-04       Impact factor: 5.922

2.  In vivo metabolism of a mutant form of apolipoprotein A-I, apo A-IMilano, associated with familial hypoalphalipoproteinemia.

Authors:  P Roma; R E Gregg; M S Meng; R Ronan; L A Zech; G Franceschini; C R Sirtori; H B Brewer
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

3.  Effect of the amyloidogenic L75P apolipoprotein A-I variant on HDL subpopulations.

Authors:  Monica Gomaraschi; Laura Obici; Sara Simonelli; Gina Gregorini; Alessandro Negrinelli; Giampaolo Merlini; Guido Franceschini; Laura Calabresi
Journal:  Clin Chim Acta       Date:  2011-03-31       Impact factor: 3.786

4.  Distant homology modeling of LCAT and its validation through in silico targeting and in vitro and in vivo assays.

Authors:  Cristina Sensi; Sara Simonelli; Ilaria Zanotti; Gabriella Tedeschi; Giulia Lusardi; Guido Franceschini; Laura Calabresi; Ivano Eberini
Journal:  PLoS One       Date:  2014-04-15       Impact factor: 3.240

5.  High Density Lipoproteins Inhibit Oxidative Stress-Induced Prostate Cancer Cell Proliferation.

Authors:  Massimiliano Ruscica; Margherita Botta; Nicola Ferri; Eleonora Giorgio; Chiara Macchi; Guido Franceschini; Paolo Magni; Laura Calabresi; Monica Gomaraschi
Journal:  Sci Rep       Date:  2018-02-02       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.